Dr. Xie is an associate professor in Pharmacometrics and Ph.D. supervisor. He graduated with a doctorate degree from Ghent University in Belgium in September 2019 and joined the Xiangya School of Pharmaceutical Sciences, Central South University in October of the same year. Currently, his main research focuses on nonlinear mixed-effects models (e.g., population pharmacokinetics and pharmacodynamics), physiologically based pharmacokinetics, and bioanalysis. Leveraging these methodologies, he is deeply immersed in the field of model-informed precision dosing (MIPD) of antibacterial drugs tailored for special populations (such as newborns, pregnant women, critically ill patients, and patients undergoing blood filtration), as well as model-informed clinical evaluation on pulmonary inhalation and transdermal drug formulations. He has led 2 projects supported by the National Natural Science Foundation and 4 provincial-level projects. He was selected for the Hunan Province Young Science and Technology Talents /Huxiang Young Elite Program and has published over 30 SCI papers as the first or corresponding author.

Email: feifan.xie@csu.edu.cn    

Professional Affiliations & Activities
• From 2022 to present: Member of the Quantitative Pharmacology Committee, Chinese Pharmacological Society
• From 2022 to present: Youth Member of the Clinical Pharmacology Committee, Chinese Pharmacological Society
• From 2022 to present: Youth Member of the Drug Metabolism Committee, Chinese Pharmacological Society
• From 2020 to present: Member of the Pharmaceutics Committee, Hunan Pharmaceutical Association

Funding acquired as Principal Investigator
• National Natural Science Foundation of China, Youth Science Fund Project, 82104306, Combination of Dried Blood Spot Method and Pharmacometric Model to Evaluate the Rational Use of Piperacillin/Tazobactam in Infant Patients Under 2 Months, January 1, 2022, to December 31, 2024, 300,000 RMB, Ongoing, Principal Investigator
• National Natural Science Foundation of China, General Project, 82073940, PK/PD Model-guided Rational Treatment of Carbapenem Antibiotics in Septic Patients Undergoing Continuous Renal Replacement Therapy, January 1, 2021, to December 31, 2024, 560,000 RMB, Ongoing, Principal Investigator
• Hunan Provincial Natural Science Foundation of China, General Project, 2024JJ5465, Combination of in vitro Dynamic PK/PD Bacterial Killing Model and Metabolomics Approach to Investigate Polymyxin B Based Combination Therapy for CRKP Infection and its Synergistic Antibacterial Mechanism, January 2024 to December 2026, 50,000 RMB, Ongoing, Principal Investigator
• Department of Science and Technology of Hunan Province, Hunan Provincial Science and Technology Innovation Program (Talent Category), 2022RC1229, Young Science and Technology Talent Project, September 2022 to September 2025, 400,000 RMB, Ongoing, Principal Investigator
• Department of Education of Hunan Province, Outstanding Youth Project, 21B0013, Evaluation of PK/PD Targets and Rational Drug Treatment of Ceftazidime/Sulbactam in Patients Undergoing Continuous Renal Replacement Therapy, December 2021 to December 2023, 60,000 RMB, Completed, Principal Investigator
• Hunan Provincial Natural Science Foundation of China, Youth Fund Project, 2021JJ40815, "Polyanion-Metal Ion-Blocking Reagent" Based Phospholipid Removal Technology to Address Matrix Effects in LC-MS/MS-Based Bioanalysis, January 2021 to December 2023, 50,000 RMB, Completed, Principal Investigator

Representative Publications in Antimicrobial Field
1. Zhang X, Wang Y, Li S, Xie F (Co-corresponding author), Yi H. Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrob Agents Chemother. 2024;68(3):e0154123.
2. Peng Y, Minichmayr IK, Liu H, Xie F (Co-corresponding author), Friberg LE. Multistate modeling for survival analysis in critically ill patients treated with meropenem. CPT Pharmacometrics Syst Pharmacol. 2024;13(2):222-233.
3. Liu Q, Li S, Xie F (Corresponding author). Linezolid dosing in critically ill patients undergoing various modalities of renal replacement therapy: a pooled population pharmacokinetic analysis. Int J Antimicrob Agents. 2023;62(4):106949.
4. Wang Y, Liu L, Wu Q, Yin Q, Xie F (Corresponding author). Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model. Antibiotics (Basel). 2022;11(11):1660.
5. Peng Y, Cheng Z, Xie F (Corresponding author). Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2022;66(9):e0082222.
6. He S, Cheng Z, Xie F (Corresponding author). Pharmacokinetic/pharmacodynamic-guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram. Int J Antimicrob Agents. 2022;59(6):106600.
7. Xie F, Wang Y, Peng Y, Cheng Z, Li S. Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. J Antimicrob Chemother. 2021;76(9):2335-2341.
8. Xie F (Corresponding author), Li S, Cheng Z. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. J Antimicrob Chemother. 2020;75(6):1559-1566.
9. Li S, Xie F (Corresponding author). Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2019;53(1):98-105.
10. Xie F (Corresponding author), Mantzarlis K, Malliotakis P, Koulouras V, Degroote S, Koulenti D, Blot S, Boussery K, Van Bocxlaer J, Colin P; LIMOP study collaborators. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. J Antimicrob Chemother. 2019;74(3):667-674.

Teaching Responsibilities
Biopharmaceutics and Pharmacokinetics (undergraduate course), Drug Analysis (undergraduate course), Advanced Biopharmaceutics and Pharmacokinetics (graduate course), and Advances in Pharmaceutics Research (graduate course).